Company intelligence / Profile preview

EyeSonix

Los Angeles, California, United Stateseyesonix.net ↗

Ownership: Private
Employees: ~3
Development stage: Preclinical

Overview

EyeSonix is developing a non-invasive, low-power therapeutic ultrasound device intended to lower intraocular pressure as a first-line treatment for glaucoma. The TULIP/TUG system is designed to be comfortable, repeatable, and potentially effective for up to a year per procedure. Claims include reduction of intraocular pressure, possible recovery of visual field, and increase in retinal nerve fiber layer thickness. Hundreds of patients have been treated over more than a decade with post-treatment follow-up; however, pivotal clinical studies confirming these claims are still pending. The product remains investigational.

Therapeutic areas: Ophthalmology
Modalities: DeviceTherapeutic ultrasound
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

TULIP

Pre-clinical

Indications: Glaucoma

Beyond the preview

Go deeper on EyeSonix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EyeSonix.

Explore the full profile